

## Supplemental Disclosure for Change of Control Events

**Active Health Foods, Inc.**  
1350 Wooten Lake Road STE 208  
Kennesaw, GA 30144  
etrnlcosmetics.com  
678-514-7316  
[Joe@etrnlcosmetics.com](mailto:Joe@etrnlcosmetics.com)

The goal of this disclosure is to provide information with respect to a company's Change of Control event. Please address each of the below items to the best of the company's ability and to the extent they are applicable to the company's Change of Control event.

### Disclosure of Change in Control and Other Material Events:

1. A description of event(s) and relevant date(s) resulting in the Change in Control.<sup>1</sup>

As reported on the Quarterly Report for June 30, 2022 filed with the OTC, on June 9 Scott Joseph Wallace (Wallace) transferred his Series A Preferred Shares of AHFD to Robert Boyar (Boyar) and resigned his positions as Sole Director, CEO, and Treasurer. Boyar became Chairman of AHFD and a Director. In addition, Dr. Gary Aaron was appointed a Director of AHFD as well as CEO. Wallace remains as President.

2. The name(s) of person(s) who acquired control and person(s) from whom control was assumed. For corporations or other business entities, please provide the name(s) of person(s) beneficially owning or controlling such corporations or entities.<sup>2</sup>

Boyar obtained the control block of Series A Preferred Shares of AHFD from Wallace.

3. A description of assets acquired or disposed of in connection with the Change in Control and the names of the purchaser and seller of such assets (if applicable).

10,000 Series A Preferred Shares of AHFD, which shares have Super Voting Rights that represents Fifty-One Percent of all authorized present and future issued common shares of AHFD.

---

<sup>1</sup> A "Change in Control" shall mean any events resulting in:

- i. Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- ii. The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- iii. A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- iv. The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

<sup>2</sup> See, Securities Exchange Act Rule 13d-3 for determination of "beneficial owner."

4. Amount and form (e.g., cash, equity securities, promissory note) of consideration paid in connection with the Change in Control.

The purchase price was \$500,000: \$50,000 cash and a Convertible Note for \$450,000.

5. A description of any material agreements or other events related to the Change in Control.

Share Purchase Agreement By And Between: Shareholders Of Bioidentical Hormones Inc.(Seller) And Active Health Foods, Inc. (Purchaser) For The Purchase Of Bioidentical Hormones Inc. (Company)

Convertible Promissory Note Issued from Active Health Foods, Inc. to Joseph Scott Wallace  
Dated: June 7, 2022 for USD \$450,000

**Certification:**

June 7, 2022

/s/Robert M. Boyar

Chairman